AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22104320 — intervention group
Group type: EXPERIMENTAL
Intervention: ½ cup of black-eyed peas for 8 weeks (Study 1)
Number of subjects: 86
Study 22104320 — intervention group
Group type: EXPERIMENTAL
Intervention: ½ cup of baked beans for 8 weeks (Study 2)
Number of subjects: 86
Study 22104320 — intervention group
Group type: COMPARATOR
Intervention: Control (canned carrots) for 8 weeks (Study 1)
Number of subjects: 86
Study 22104320 — intervention group
Group type: COMPARATOR
Intervention: Control (canned carrots) for 8 weeks (Study 2)
Number of subjects: 86
Study 22104320 — intervention group
Group type: EXPERIMENTAL
Intervention: ½ cup of pinto beans for 12 weeks (Study 3)
Number of subjects: 86
Study 22104320 — intervention group
Group type: COMPARATOR
Intervention: Control soup for 12 weeks (Study 3)
Number of subjects: 86
Study 19419845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Pindolol
Number of subjects: 0
Study 19419845 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine + Placebo
Number of subjects: 0
Study 16684688 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (Ventoline Diskhaler) 200 microg three times a day
Number of subjects: 15
Study 16684688 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study 15461065 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 643
Study 15461065 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 643
Study 15461065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 11736858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0
Study 11736858 — intervention group
Group type: COMPARATOR
Intervention: (+)-chlorpheniramine 2 mg
Number of subjects: 0
Study 11736858 — intervention group
Group type: COMPARATOR
Intervention: (+)-chlorpheniramine 6 mg
Number of subjects: 0
Study 9246150 — intervention group
Group type: EXPERIMENTAL
Intervention: Single i.v. dolasetron dose (0.6 mg/kg) before cisplatin
Number of subjects: 30
Study 9246150 — intervention group
Group type: COMPARATOR
Intervention: Multiple i.v. dose regimen (0.6 mg/kg x 3) given before and after cisplatin
Number of subjects: 30
Study 7975420 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple powder
Number of subjects: 38
Study 3442398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 17
Study 3442398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3442398 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill plus isometric exercise
Number of subjects: 17
Study 3442398 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill test
Number of subjects: 17
Study 31160146 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day for four days)
Number of subjects: 41
Study 31160146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for four days)
Number of subjects: 41
Study 28851462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based behavior-change intervention during inpatient pulmonary rehabilitation
Number of subjects: 502
Study 28851462 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pulmonary rehabilitation without the pedometer-based intervention)
Number of subjects: 502
Study 25958096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomer flap (VF) protocol
Number of subjects: 200
Study 25958096 — intervention group
Group type: COMPARATOR
Intervention: Two-flap technique (TF) protocol
Number of subjects: 200
Study 23379397 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel education intervention (n = 40)
Number of subjects: 79
Study 23379397 — intervention group
Group type: COMPARATOR
Intervention: Traditional code blue and rapid response education (Control group, n = 39)
Number of subjects: 79
Study 21591241 — intervention group
Group type: COMPARATOR
Intervention: Low Protein / High Glycemic Index diet
Number of subjects: 548
Study 21591241 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein / Low Glycemic Index diet
Number of subjects: 548
Study 21591241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index diets (high or low protein content)
Number of subjects: 548
Study 19696637 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (prednisone) for 3 months
Number of subjects: 32
Study 19696637 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (prednisone, cyclosporine, and mycophenolate)
Number of subjects: 32
Study 16877210 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted wound closure (VAC) technique
Number of subjects: 24
Study 16877210 — intervention group
Group type: COMPARATOR
Intervention: Conventional wet dressing technique (CWD)
Number of subjects: 24
Study 12921212 — intervention group
Group type: EXPERIMENTAL
Intervention: Desistors
Number of subjects: 80
Study 12921212 — intervention group
Group type: COMPARATOR
Intervention: Persistors
Number of subjects: 80
Study 10710839 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy homework compliance
Number of subjects: 0
Study 9200166 — intervention group
Group type: EXPERIMENTAL
Intervention: Long wavelength pass filters dispensed as tinted spectacles
Number of subjects: 0
Study 8259034 — intervention group
Group type: EXPERIMENTAL
Intervention: Total therapeutic paracentesis (TTP) plus i.v. albumin (5 g/l of fluid)
Number of subjects: 35
Study 8259034 — intervention group
Group type: COMPARATOR
Intervention: Total therapeutic paracentesis (TTP) without albumin
Number of subjects: 35
Study 3519644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25 mg twice daily, increased to 2.5 mg twice daily if no improvement)
Number of subjects: 55
Study 3519644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 3519644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 55
Study 3519644 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Bromocriptine and Placebo)
Number of subjects: 55
Study 3519644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day)
Number of subjects: 55
Study 29439359 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-HF rTMS (1 Hz to the contralesional hemisphere followed by 10 Hz to the lesional hemisphere)
Number of subjects: 62
Study 29439359 — intervention group
Group type: COMPARATOR
Intervention: LF-rTMS (1 Hz to the contralesional hemisphere)
Number of subjects: 62
Study 29439359 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 62
Study 28688525 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-guided dose-escalation (mean doses of 95Gy for tumour and 74Gy for lymph nodes)
Number of subjects: 30
Study 28688525 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (66Gy/33F plans)
Number of subjects: 30
Study 25714724 — intervention group
Group type: EXPERIMENTAL
Intervention: A standardized extract from Ageratina pichinchensis (5 %, cream formulation)
Number of subjects: 0
Study 25714724 — intervention group
Group type: COMPARATOR
Intervention: Micronized silver sulfadiazine (1 %)
Number of subjects: 0
Study 22836585 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg/week in addition to TPTD
Number of subjects: 125
Study 22836585 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RAL) 60 mg/d in addition to TPTD
Number of subjects: 125
Study 22836585 — intervention group
Group type: COMPARATOR
Intervention: TPTD monotherapy (no additional medication)
Number of subjects: 125
Study 21729676 — intervention group
Group type: EXPERIMENTAL
Intervention: FUFIRI (5-fluorouracil [5-FU], leucovorin, irinotecan)
Number of subjects: 479
Study 21729676 — intervention group
Group type: COMPARATOR
Intervention: mIROX (modified irinotecan plus oxaliplatin)
Number of subjects: 479
Study 21729676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 479
Study 19148787 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 19148787 — intervention group
Group type: COMPARATOR
Intervention: Non-NSAID users
Number of subjects: 0
Study 16464979 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial ropivacaine 0.2% (Group R)
Number of subjects: 48
Study 16464979 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial fentanyl 4 microg ml(‐1) (Group F)
Number of subjects: 48
Study 16464979 — intervention group
Group type: COMPARATOR
Intervention: i.v. fentanyl 4 microg ml(‐1) (Group C)
Number of subjects: 48
Study 15142198 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol (800 mg)
Number of subjects: 19
Study 15142198 — intervention group
Group type: COMPARATOR
Intervention: Balsalazide (2250 mg)
Number of subjects: 19
Study 11463965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 9762783 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol dry powder 24 microg twice daily (08:00 and 20:00 h)
Number of subjects: 10
Study 9762783 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 24 microg once daily (20:00 h)
Number of subjects: 10
Study 9762783 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 7527922 — intervention group
Group type: EXPERIMENTAL
Intervention: VLAP (Vaporization of the Prostate using Laser Ablation Procedure)
Number of subjects: 0
Study 7527922 — intervention group
Group type: COMPARATOR
Intervention: TURP (Transurethral Resection of the Prostate)
Number of subjects: 0
Study 2500692 — intervention group
Group type: EXPERIMENTAL
Intervention: Naaga (the magnesium salt of N‐acetyl‐aspartyl‐glutamate)
Number of subjects: 100
Study 2500692 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 100
Study 31842191 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 20
Study 28349504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravitreal bevacizumab (IVB) injection
Number of subjects: 46
Study 28349504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1.25 mg IVB and 1 mg intravitreal triamcinolone (IVT)
Number of subjects: 46
Study 28349504 — intervention group
Group type: COMPARATOR
Intervention: Combination of 1.25 mg IVB and 1 mg IVT
Number of subjects: 46
Study 26944026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 510
Study 26944026 — intervention group
Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 510
Study 24288260 — intervention group
Group type: EXPERIMENTAL
Intervention: Amide proton transfer (APT) MRI
Number of subjects: 10
Study 24288260 — intervention group
Group type: COMPARATOR
Intervention: Control white matter APT values
Number of subjects: 10
Study 24288260 — intervention group
Group type: EXPERIMENTAL
Intervention: APT signal in final infarct region
Number of subjects: 10
Study 24288260 — intervention group
Group type: EXPERIMENTAL
Intervention: APT imaging
Number of subjects: 10
Study 24251742 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger group
Number of subjects: 24
Study 24251742 — intervention group
Group type: COMPARATOR
Intervention: Weaker group
Number of subjects: 24
Study 21312288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle plus 75 g of glucose
Number of subjects: 40
Study 21312288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle plus 75 mg of caffeine
Number of subjects: 40
Study 21312288 — intervention group
Group type: EXPERIMENTAL
Intervention: Vehicle plus 75 g of glucose and 75 mg of caffeine
Number of subjects: 40
Study 21312288 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (water, 150 ml)
Number of subjects: 40
Study 18221474 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intramuscular influenza and pneumococcal heptavalent conjugate vaccinations (IV + PV)
Number of subjects: 579
Study 18221474 — intervention group
Group type: COMPARATOR
Intervention: Influenza and placebo vaccinations (IV + plac)
Number of subjects: 579
Study 18221474 — intervention group
Group type: COMPARATOR
Intervention: Control hepatitis B and placebo vaccinations (HepB + plac)
Number of subjects: 579
Study 16773418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurvedic polyherbal preparation 'Shathavaryadi Yoga (NS001)'
Number of subjects: 0
Study 16773418 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide
Number of subjects: 0
Study 12742282 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day, n = 15)
Number of subjects: 30
Study 12742282 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, n = 15)
Number of subjects: 30
Study 12742282 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 30
Study 12742282 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (Atorvastatin and Simvastatin)
Number of subjects: 30
Study 12742282 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 30
Study 10805693 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation of the sural nerve at a nonnociceptive intensity during early and late swing phases while walking on a treadmill.
Number of subjects: 2
Study 8827017 — intervention group
Group type: EXPERIMENTAL
Intervention: Prechemotherapy G‐CSF (administered subcutaneously twice per day for 5 days at a dose of 5 micrograms/kg)
Number of subjects: 36
Study 8827017 — intervention group
Group type: COMPARATOR
Intervention: Postchemotherapy G‐CSF (administered subcutaneously once per day for 7 days at a dose of 5 micrograms/kg)
Number of subjects: 36
Study 8827017 — intervention group
Group type: EXPERIMENTAL
Intervention: Prechemotherapy G‐CSF
Number of subjects: 36
Study 8827017 — intervention group
Group type: COMPARATOR
Intervention: Postchemotherapy G‐CSF
Number of subjects: 36
Study 8827017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 36
Study 1462413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g at bedtime
Number of subjects: 102
Study 1462413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 3892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy
Number of subjects: 122
Study 3892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy with positive skin test conversion
Number of subjects: 122
Study 3892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy with negative skin test
Number of subjects: 122
Study 3892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy with previously positive skin test
Number of subjects: 122
Study 3892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guerin
Number of subjects: 122
Study 3892050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin immunotherapy in high-risk patients
Number of subjects: 122
Study 30920684 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive processing therapy
Number of subjects: 108
Study 30920684 — intervention group
Group type: EXPERIMENTAL
Intervention: Group present-centered therapy
Number of subjects: 108
Study 30920684 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonhazardous drinkers)
Number of subjects: 108
Study 29081351 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE) plus pill placebo
Number of subjects: 0
Study 29081351 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (SERT) plus Enhanced Medication Management (EMM)
Number of subjects: 0
Study 29081351 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (PE/SERT)
Number of subjects: 0
Study 27560289 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic monodensified hyaluronic acid (MMHA)
Number of subjects: 49
Study 27560289 — intervention group
Group type: COMPARATOR
Intervention: Biphasic nonanimal stabilized hyaluronic acid (BHA)
Number of subjects: 49
Study 24343370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated on CPB (VG)
Number of subjects: 30
Study 24343370 — intervention group
Group type: COMPARATOR
Intervention: Non-ventilated CPB group (NVG)
Number of subjects: 30
Study 24343370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 23700945 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous omega-3 PUFAs (Omegaven 10%) infusion
Number of subjects: 40
Study 23700945 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution infusion (control group)
Number of subjects: 40
Study 20973604 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory training program
Number of subjects: 0
Study 20973604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18072874 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact jumping exercises
Number of subjects: 57
Study 18072874 — intervention group
Group type: COMPARATOR
Intervention: Nonimpact stretching activities
Number of subjects: 57
Study 16168733 — intervention group
Group type: EXPERIMENTAL
Intervention: Generation of Hypotheses test (Left Lateral subgroup)
Number of subjects: 46
Study 16168733 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of the Rule test (Left Lateral subgroup)
Number of subjects: 46
Study 16168733 — intervention group
Group type: EXPERIMENTAL
Intervention: Generation of Hypotheses test (Right Lateral subgroup)
Number of subjects: 46
Study 16168733 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of the Rule test (Right Lateral subgroup)
Number of subjects: 46
Study 16168733 — intervention group
Group type: EXPERIMENTAL
Intervention: Generation of Hypotheses test (Medial subgroup)
Number of subjects: 46
Study 16168733 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of the Rule test (Medial subgroup)
Number of subjects: 46
Study 12973173 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution (30% glucose in water with insulin 50 U/L, and KCl 40 mM/L) at 1.5 mL/kg/hr for 24 hrs
Number of subjects: 37
Study 12973173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 10696980 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b, colchicine, and benzathine penicillin
Number of subjects: 135
Study 10696980 — intervention group
Group type: COMPARATOR
Intervention: Colchicine and benzathine penicillin alone
Number of subjects: 135
Study 10696980 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 135
Study 10696980 — intervention group
Group type: COMPARATOR
Intervention: No interferon therapy
Number of subjects: 135
Study 9024895 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 20
Study 9024895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1891078 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 17
Study 1891078 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 3519241 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine in addition to hydrochlorothiazide
Number of subjects: 12
Study 3519241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31260028 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored 12-minute stroke films
Number of subjects: 312
Study 31260028 — intervention group
Group type: COMPARATOR
Intervention: Usual care (stroke education pamphlets)
Number of subjects: 312
Study 31260028 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored 12-minute stroke films (low-education subgroup)
Number of subjects: 312
Study 31260028 — intervention group
Group type: COMPARATOR
Intervention: Usual care (low-education subgroup)
Number of subjects: 312
Study 31260028 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored 12-minute stroke films (high-education subgroup)
Number of subjects: 312
Study 31260028 — intervention group
Group type: COMPARATOR
Intervention: Usual care (high-education subgroup)
Number of subjects: 312
Study 29863386 — intervention group
Group type: EXPERIMENTAL
Intervention: consumed-sugar/told-sugar
Number of subjects: 105
Study 29863386 — intervention group
Group type: EXPERIMENTAL
Intervention: consumed-sugar/told-no-sugar
Number of subjects: 105
Study 29863386 — intervention group
Group type: COMPARATOR
Intervention: consumed-no-sugar/told-sugar
Number of subjects: 105
Study 29863386 — intervention group
Group type: COMPARATOR
Intervention: consumed-no-sugar/told-no-sugar
Number of subjects: 105
Study 26184035 — intervention group
Group type: COMPARATOR
Intervention: Standard shoes + ankle-foot orthosis
Number of subjects: 30
Study 26184035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker shoes + ankle-foot orthosis
Number of subjects: 30
Study 23511293 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (dosage: 300 mg TID, 600 mg TID, 800 mg TID, 1200 mg TID)
Number of subjects: 53
Study 23511293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 23511293 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 53
Study 22541659 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAEK
Number of subjects: 118
Study 22541659 — intervention group
Group type: COMPARATOR
Intervention: PK
Number of subjects: 118
Study 22541659 — intervention group
Group type: COMPARATOR
Intervention: FS-DSEK
Number of subjects: 118
Study 22541659 — intervention group
Group type: COMPARATOR
Intervention: DSAEK vs PK
Number of subjects: 118
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression at 1 year
Number of subjects: 100
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression at 2 years
Number of subjects: 100
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety at 1 year
Number of subjects: 100
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety at 2 years
Number of subjects: 100
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of depression at 1 year
Number of subjects: 100
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of anxiety at 1 year
Number of subjects: 100
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of depression at 2 years
Number of subjects: 100
Study 20302988 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of anxiety at 2 years
Number of subjects: 100
Study 22423114 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain multivariate pattern-based analysis (MVPA)
Number of subjects: 0